NCT04741165

Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)

An Open-label, Multicenter, Phase II Clinical Study of HX008 in Combination With Bevacizumab or Lenvatinib in Patients With Advanced Hepatocellular Carcinoma (HCC)

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: Taizhou Hanzhong biomedical co. LTD · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center,open-label study to evaluate the efficacy and safety of anti-PD-1 antibody HX008 plus bevacizumab or lenvatinib in the first-line treatment of patients with unresectable hepatocellular carcinoma.

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	HX008	200 mg administered as IV infusion on Day 1 of each 21-day cycle.
DRUG	Bevacizumab	15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.
DRUG	Lenvatinib	Administered orally once a day during each 21-day cycle

Timeline

• Start date: 2021-01-07
• Primary completion: 2022-04-30
• Completion: 2022-10-30
• First posted: 2021-02-05
• Last updated: 2021-02-05

Locations

13 sites across 1 country: China